First of all a very big thanks for bringing that question up at the AGM.
I don't think a cross over trial would be that complex to design and those patients that cross over would in fact be those that would be eligible for a recruitment in a trial that SI described, could actually be better as they most likely would not have been given many of the other drugs that are experimental other than those given as a sedation for ventilation . It is possible that those drugs have a negative impact on outcomes as well.
My understanding from SI was that the trial design was a little bit undecided. Leaving it a bit open for discussion with the FDA, perhaps his team will bring forward several trial designs for the FDA to consider and set suitable endpoints. Would also be a little hesitant as Novartis would probably want to add there exspert
opinion in as well.
Good luck all and stay safe.
- Forums
- ASX - By Stock
- MSB
- Ann: CEO Presentation to 2021 Annual General Meeting
Ann: CEO Presentation to 2021 Annual General Meeting, page-48
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.15 |
Change
-0.105(8.37%) |
Mkt cap ! $1.313B |
Open | High | Low | Value | Volume |
$1.22 | $1.23 | $1.14 | $9.583M | 8.106M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | $1.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.16 | 25000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 1.150 |
9 | 110632 | 1.145 |
11 | 486131 | 1.140 |
2 | 74852 | 1.135 |
8 | 295301 | 1.130 |
Price($) | Vol. | No. |
---|---|---|
1.155 | 25000 | 2 |
1.160 | 25000 | 1 |
1.165 | 48667 | 3 |
1.170 | 38440 | 2 |
1.175 | 39740 | 4 |
Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |